Shares of Atrion Co. (NASDAQ:ATRI) have earned a consensus broker rating score of 5.00 (Strong Sell) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong sell recommendation.
Analysts have set a one year consensus price objective of $300.00 for the company, according to Zacks. Zacks has also assigned Atrion an industry rank of 216 out of 255 based on the ratings given to its competitors.
Separately, BidaskClub lowered Atrion from a “buy” rating to a “hold” rating in a research note on Tuesday, August 28th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in Atrion during the second quarter worth $240,000. Xact Kapitalforvaltning AB acquired a new position in shares of Atrion in the 1st quarter valued at $248,000. Principal Financial Group Inc. acquired a new position in shares of Atrion in the 1st quarter valued at $249,000. Chevy Chase Trust Holdings Inc. acquired a new position in shares of Atrion in the 2nd quarter valued at $300,000. Finally, Bank of Montreal Can acquired a new position in shares of Atrion in the 2nd quarter valued at $362,000. 61.11% of the stock is currently owned by institutional investors.
NASDAQ ATRI opened at $680.60 on Friday. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 38.15 and a beta of 0.56. Atrion has a fifty-two week low of $516.85 and a fifty-two week high of $718.11.
Atrion (NASDAQ:ATRI) last released its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $4.70 earnings per share for the quarter. The company had revenue of $38.85 million for the quarter. Atrion had a return on equity of 17.99% and a net margin of 22.57%.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 14th were paid a dividend of $1.35 per share. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $5.40 dividend on an annualized basis and a yield of 0.79%. This is a positive change from Atrion’s previous quarterly dividend of $1.20.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Article: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.